Is a patient with elevated pulmonary artery pressure (PA) of 28 mmHg, pulmonary capillary wedge pressure (PCW) of 16 mmHg, and cardiac output (CO) of 2.98 L/min indicative of Group 2 pulmonary hypertension due to left heart disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 16, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Hemodynamic Classification of This Patient

Yes, these hemodynamic values are consistent with Group 2 pulmonary hypertension (PH due to left heart disease), specifically isolated post-capillary PH. 1

Hemodynamic Analysis

Your patient's values meet the diagnostic criteria for post-capillary PH:

  • Mean PA pressure of 28 mmHg meets the threshold for PH (≥25 mmHg by 2015 guidelines, ≥20 mmHg by newer definitions) 2
  • PCWP of 16 mmHg is elevated (>15 mmHg), which is the critical distinguishing feature that defines post-capillary PH 1, 2
  • Cardiac output of 2.98 L/min is reduced, indicating compromised cardiac function 1

Calculating Pulmonary Vascular Resistance

To definitively classify this as isolated versus combined post-capillary PH, you must calculate PVR:

PVR = (mPAP - PCWP) / CO = (28 - 16) / 2.98 = 4.03 Wood units 3

This PVR of 4.03 Wood units is >3 Wood units, which technically meets criteria for combined post-capillary and pre-capillary PH (Cpc-PH) rather than isolated post-capillary PH 1, 2. This indicates superimposed pulmonary vascular disease with vasoconstriction and remodeling beyond passive congestion alone 1.

Clinical Significance

Combined post-capillary and pre-capillary PH carries worse prognosis than isolated post-capillary PH 1. The diastolic pressure gradient (DPG) provides additional prognostic information:

  • DPG = diastolic PAP - mean PCWP 2
  • If DPG ≥7 mmHg, this confirms Cpc-PH and is associated with increased mortality 1

Diagnostic Workup Required

To confirm Group 2 PH, look for these clinical features that strongly suggest left heart disease rather than other PH groups 1:

  • Age >65 years
  • Symptoms of left heart failure (orthopnea, paroxysmal nocturnal dyspnea)
  • Features of metabolic syndrome
  • History of coronary artery disease, hypertension, or valvular disease
  • Persistent atrial fibrillation

Echocardiographic findings supporting Group 2 PH include 1:

  • Structural left heart abnormality
  • Doppler indices of increased LV filling pressures
  • Bowing of inter-atrial septum to the right

Management Approach

The primary treatment goal is optimizing management of the underlying left heart disease 1, 4, 5. This includes:

  • Aggressive heart failure therapy with guideline-directed medical therapy 5
  • Repair of valvular disease when indicated 1
  • Optimizing volume status 1
  • Controlling cardiovascular risk factors 1

Critical caveat: PAH-specific therapies (phosphodiesterase-5 inhibitors, endothelin receptor antagonists, prostacyclin analogues) are not indicated for Group 2 PH and should only be used for Group 1 PAH 4, 5. Current data for these agents in post-capillary PH remain limited and conflicting 5.

Common Pitfalls to Avoid

  • Do not rely on echocardiography alone for hemodynamic classification—right heart catheterization remains the gold standard 1
  • Ensure accurate PCWP measurement by zeroing the transducer at mid-thoracic line and measuring at end-expiration during spontaneous breathing 3
  • Consider direct left atrial pressure measurement if PCWP seems inaccurate or if there is clinical-hemodynamic discrepancy 3
  • Recognize that elevated PCWP alone may not always indicate left heart disease—consider calculating transmural pressure difference (PCWP - RAP) for additional diagnostic accuracy 6

References

Guideline

Hemodynamic Distinction Between Pre-Capillary and Post-Capillary Pulmonary Hypertension

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Calculation of Pulmonary and Systemic Vascular Resistance

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Pulmonary Hypertension: A Brief Guide for Clinicians.

Mayo Clinic proceedings, 2020

Research

Post-Capillary Pulmonary Hypertension: Clinical Review.

Journal of clinical medicine, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.